Michael J. Birrer, MD of Massachusetts General Hospital discusses multiplex testing and next generation sequencing in metastatic ovarian cancer at SGO 2016.
So this is a really high question. Because there are many many commercially available platforms which provide a lot of genomic data both for the physician and the patient. I and I think frankly is more often than not confusing. For both individuals. What I recommend because. Ovarian cancer is a disease of genomics chaos. There's a very low frequency of actionable mutations and even when you see a mutation in a gene that you think is actionable. Are we don't have the and understand the biology to tell you where that's going to mean anything for the patient. So I limit my sequencing to those genes that would define homologous recombination defense. So these would be BRCA 1 and BRCA 2 and many the genes are low. In the Fanconi DNA repair pathway those are important because first of all if they're associating a germ line it has implications. For the family. And risk of development of a very cancer and to now that part of the class of agents called part inhibitors have been approved it is fair to assume their view of a patient who has a mutation one of those genes that their tumor may be responsive department Evers.
B.J. Rimel, MD of Cedars Sinai Medical Center discusses the SGO 2016 highlights and trends from SGO 2016.
I think that the array of options. For testing whether it be genetic panel testing with multiple multiple genes. Or is it a ray of immunotherapy auctions are probably the two strongest trends I see here at this meeting. There's a lot of work that remains to be done to see how that's going to play out for patients I think that clinicians and providers. And patients need to be aware of these options before we run headlong into these be aware of the risks the benefits. The potential outcomes both good and bad I think clinical trials are incredibly valuable as we start all the stuff out elements are really appreciate all the patients that devote themselves to being on a clinical trial.
B.J. Rimel, MD of Cedars Sinai Medical Center discusses the next 5 years in gynaecologic malignancies treatment from SGO 2016.
I think that we're going to continue become more multi disciplinary then we have been. Gynecologic oncology is. Expanding in the types of people that are practicing it medical oncologist being included in our society pharmacist nurse. Shares position of. Students. Our frozen residents I think it's just an incredibly expanding field and I think that that's going to be a wonderful opportunity for us to draw on the experiences of other disciplines to help better treat our.
B.J. Rimel, MD of Cedars Sinai Medical Center discusses the high number of uterine and BRCA mutations from study focusing on endometrial cancer patients from SGO 2016.
There is another abstract by doctor ring that looked at and unselected cohort of individual cancer patients that have been panel tested and soon there some pretty remarkable findings from. Paper I specifically that there were urine cancers that had opposed. Surprisingly high number of mutations that were previously unknowns there there are some recommendations in their serious cancers which is really interesting more data will be very valuable and try to figure out what that means for patients.
B.J. Rimel, MD of Cedars Sinai Medical Center discusses the future clinical trials in ovarian cancer from SGO 2016.
In terms of future clinical trials. There we are selecting more clinical trials based on. Known genetic predispositions be RCA. The potential response to platinum potential response to part now being a sort of thing that we're looking at. So all of these panel testings are going to lead us down different pathways and so that does make us help a stratified patients for future study for clinical trials. Probably the direction I see that going on right now.